Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial

Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial

An online expert meeting held on November 17, 2021 reviewed the results of the randomized, double-blind, multinational, parallel-group EMPULSE trial, evaluating the clinical benefit and safety of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin compared with placebo in patients h...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. M. Lopatin, G. P. Arutyunov, A. S. Ametov, F. T. Ageev, M. B. Antsiferov, O. L. Barbarash, S. V. Villevalde, N. G. Vinogradova, G. R. Galstyan, A. S. Galyavich, S. R. Gilyarevsky, M. G. Glezer, I. V. Zhirov, M. V. Ilyin, A. Yu. Lebedeva, S. V. Nedogoda, V. V. Salukhov, E. I. Tarlovskaya, S. N. Tereshchenko, I. V. Fomin, Yu. Sh. Khalimov, D. V. Cherkashin
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2022-04-01
Series:Российский кардиологический журнал
Subjects:
empagliflozin
heart failure
hospitalization
acute decompensated heart failure
empulse trial
win ratio analysis
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4945
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://russjcardiol.elpub.ru/jour/article/view/4945

Similar Items